From May 13‑16, more than 500 scientists, drug developers and regulators gathered in Shanghai’s Zhangjiang Science City for the 2026 DIA Drug Information Conference. Twelve major drug‑regulating agencies from around the world attended, marking an unprecedented show of confidence in China’s fast‑growing biotech sector. Organisers highlighted that Shanghai’s biomedical industry is now worth over a trillion yuan, with manufacturing output close to 210 billion yuan and 48 overseas licensing deals worth $33.8 billion. Experts said Chinese innovation is no longer limited to late‑stage trials; companies in Pudong are now leading early‑stage research, creating breakthrough therapies such as the first‑in‑the‑world MET‑exon‑14 lung‑cancer drug from Hutchmed and the nation’s first KRAS‑G12D inhibitor from Jingfang Pharma. The conference featured closed‑door talks on AI‑driven drug discovery and cell‑gene therapies, and showcased how Chinese firms are building “trust bridges” that help their medicines reach global markets. With more than 1,400 innovative drug projects in the pipeline, Pudong is positioning itself as a world‑class hub where home‑grown breakthroughs can quickly become international treatments.
Read moreA new review in the *Orphanet Journal of Rare Diseases* maps the fast‑moving world of medical‑device innovation for rare and childhood illnesses. Researchers surveyed global R&D pipelines, highlighting a surge in small‑batch, high‑precision tools—such as gene‑editing implants, wearable heart monitors for congenital conditions, and portable dialysis units—designed to reach patients that traditional pharmaceuticals often miss. At the same time, China’s National Medical Products Administration (NMPA) is tightening oversight, launching a more targeted safety‑risk consultation system and publishing a 2024‑updated list of mandatory device standards to ensure quality across the expanding market. The article also shares real‑life stories: a 18‑year‑old with delayed growth finally diagnosed after a novel imaging device, a child whose fainting spells were traced to a hereditary heart defect thanks to a new portable ECG, and the inaugural World Neurofibromatosis Care Day that celebrated the first approved therapy for a previously untreatable condition. Platforms like MedSci are linking doctors, patients, and manufacturers with AI‑driven data tools, accelerating clinical trials and improving access. Together, tighter regulation, clearer standards, and breakthrough technologies are reshaping the landscape, offering hope to millions of rare‑disease and pediatric patients worldwide.
Read more